BACKGROUND: Hypophosphatemia appears to be a universal event after right hepatic lobectomy for live-donor adult liver transplantation according to one report. Because hypophosphatemia appears to contribute to increased postoperative complications, routine hyperalimentation with supratherapeutic levels of phosphorus was advocated. METHODS: From July 2000 to May 2002, we performed 95 right-lobe living-donor hepatectomies for 95 adult liver-transplant recipients, the largest single institutional experience. We reviewed our data that were collected prospectively. RESULTS: We did not find profound hypophosphatemia (<1.0 mg/dL) to be prevalent in our donors. At least six (6.3%) donors did not have postoperative hypophosphatemia. In addition, there appears to be no increased morbidity related to hypophosphatemia when aggressively corrected with intravenous or oral phosphates in our group of donors that underwent right-lobe hepatectomies. CONCLUSIONS: We, therefore, cannot endorse the routine administration of hyperalimentation with supratherapeutic phosphorus because of its potential morbidity.
BACKGROUND:Hypophosphatemia appears to be a universal event after right hepatic lobectomy for live-donor adult liver transplantation according to one report. Because hypophosphatemia appears to contribute to increased postoperative complications, routine hyperalimentation with supratherapeutic levels of phosphorus was advocated. METHODS: From July 2000 to May 2002, we performed 95 right-lobe living-donor hepatectomies for 95 adult liver-transplant recipients, the largest single institutional experience. We reviewed our data that were collected prospectively. RESULTS: We did not find profound hypophosphatemia (<1.0 mg/dL) to be prevalent in our donors. At least six (6.3%) donors did not have postoperative hypophosphatemia. In addition, there appears to be no increased morbidity related to hypophosphatemia when aggressively corrected with intravenous or oral phosphates in our group of donors that underwent right-lobe hepatectomies. CONCLUSIONS: We, therefore, cannot endorse the routine administration of hyperalimentation with supratherapeutic phosphorus because of its potential morbidity.
Authors: Ivo Giovannini; Carlo Chiarla; Felice Giuliante; Francesco Ardito; Maria Vellone; Gennaro Nuzzo Journal: Ann Surg Date: 2006-03 Impact factor: 12.969
Authors: Julie Hallet; Paul J Karanicolas; Francis S W Zih; Eva Cheng; Julia Wong; Sherif Hanna; Natalie G Coburn; Calvin H L Law Journal: Hepatobiliary Surg Nutr Date: 2016-06 Impact factor: 7.293
Authors: Malcolm H Squires; Gregory C Dann; Neha L Lad; Sarah B Fisher; Benjamin M Martin; David A Kooby; Juan M Sarmiento; Maria C Russell; Kenneth Cardona; Charles A Staley; Shishir K Maithel Journal: HPB (Oxford) Date: 2014-05-15 Impact factor: 3.647